ArticleFrontiers in pharmacology2025
Case Report: Botulism associated with cosmetic BoNT-A injections: respiratory failure and multidrug-resistant infection as emerging clinical challenges.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Botulism is a life-threatening neurotoxin-mediated disease characterized by flaccid descending paralysis which begins with cranial nerve palsies and might progress to extremity weakness and respiratory failure. Respiratory failure following cosmetic injections were scarcely reported due to the low dose of botulinum neurotoxin type A (BoNT-A) used. We present two cases of respiratory failure and multi-drug resistant (MDR) bacteria infection resulted from botulism following cosmetic injections. A 24-year-old female developed symptoms of dysphagia, blurred vision and dysarthria 6 days after cosmetic injections of BoNT-A, and progressed to respiratory failure which needed invasive mechanical ventilation 5 days later. Another 46-year-old female developed dizziness, headache and nausea 30 min after cosmetic injections of BoNT-A. Symptoms including ptosis, blurred vision, dysphagia, and slurred speech appeared 1 week later. The patient received mechanical ventilation due to the deteriorated respiratory failure. Both patients developed multi-drug resistant (MDR) bacteria infection during hospitalization. Though the pneumonia improved with effective antibiotics treatment, they underwent tracheostomy or second endotracheal intubation several days after successful weaning from the ventilator. Fortunately, they recovered without significant sequelae left. The widespread application of BoNT-A increases the risk of severe adverse events including respiratory failure and MDR bacteria infections. These two cases highlight the importance of pulmonary management for those with severe cosmetic botulism and health authorities' supervision on the cosmetic injections with BoNT-A in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.